Dementia is a clinical syndrome of progressive cognitive decline with significant functional impact that affects tens of millions of people worldwide and whose prevalence increases exponentially with age: approximately 5% of older adults… Read more.
54 factors with evidence, ordered from highest to lowest effectiveness. Information, not medical advice.
⏱ 3 min read
Dementia is a clinical syndrome of progressive cognitive decline with significant functional impact that affects tens of millions of people worldwide and whose prevalence increases exponentially with age: approximately 5% of people over 65, 20% of those over 80, and almost 50% of those over 85; Alzheimer's disease is the most frequent cause (60-70% of the total), followed by vascular dementia, dementia with Lewy bodies, and frontotemporal dementia. The good news, documented by the Lancet Commission on dementia, is that approximately 40% of dementia risk is attributable to modifiable factors across the lifespan, which opens an important margin for effective prevention.
Across the life course, the modifiable risk factors for dementia are:
Early life: low educational attainment (education builds cognitive reserve).
Midlife: hearing loss (hearing aids are protective), head injury (helmets, fall prevention), hypertension, excessive alcohol, obesity.
Later life: smoking, depression, physical inactivity, limited social contact, diabetes, air pollution.
To this list, more recent data add sleep quality and quantity and diet as additional factors with growing evidence.
Regular aerobic exercise: increases BDNF, improves cerebral blood flow, increases hippocampal volume, and is associated with significant reductions in dementia incidence in prospective cohorts. Combining it with strength training preserves muscle mass and prevents falls.
Mediterranean or MIND diet: the MIND diet (a combination of Mediterranean + DASH specifically designed for cognitive preservation) is supported by cohorts and some trials for reducing the incidence of Alzheimer's disease.
Control of cardiovascular factors: hypertension, diabetes, dyslipidemia, smoking; brain health depends crucially on vascular health.
Continuous cognitive stimulation: lifelong learning, reading, cognitive games, languages; builds cognitive reserve.
Active social ties: a robust predictor of cognitive preservation.
Sufficient, good-quality sleep: during deep sleep, the glymphatic system clears brain beta-amyloid; chronic sleep deprivation increases amyloid accumulation in prospective cohorts.
Treating hearing loss: hearing aid use in adults with hearing loss reduces cognitive decline according to recent trials.
B vitamins (folate, B12, B6) in people with elevated homocysteine: the VITACOG trial showed a significant reduction in brain atrophy with this combination.
Omega-3 EPA/DHA: adequate intake is associated with a lower incidence of dementia in prospective studies; the effect of specific supplementation in people with normal cognition is modest.
Vitamin D: subclinical deficiencies are associated with higher cognitive risk.
Citicoline (500-2000 mg/day): clinical support for cognitive impairment of cerebrovascular origin and mild vascular dementia.
Alpha-GPC: supported in European countries as a medication for cognitive impairment (Glatilin); the ASCOMALVA trial showed synergy with donepezil in mild Alzheimer's disease.
Lion's mane (Hericium erinaceus): the Mori 2009 trial showed significant improvements in mild cognitive impairment.
Spermidine (wheat germ extract): inverse association with mortality and cognitive decline in cohorts.
Curcumin, various polyphenols: with extensive preclinical support and modest clinical data.
Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine are symptomatic treatments for established Alzheimer's disease with a modest effect. In 2021-2024, the first anti-amyloid monoclonal antibodies (aducanumab, lecanemab, donanemab) appeared; they reduce brain amyloid and, marginally, clinical decline in early Alzheimer's disease; they have significant adverse effects (brain edema, microhemorrhages), and the data on their real-world clinical usefulness are the subject of active debate in neurology.
Significant and progressive cognitive complaints, especially with functional impact or reported by family members, require medical evaluation to rule out treatable causes (depression, B12 deficiency, hypothyroidism, sleep apnea, drugs with cognitive effects) and for early diagnosis if there is mild cognitive impairment or established dementia; early diagnosis allows for specific interventions and appropriate family planning.
Dementia is one of the conditions where prevention through sustained lifestyle has the greatest potential: control of cardiovascular factors, regular exercise, a Mediterranean diet, adequate sleep, continuous cognitive stimulation, active social ties, and management of hearing loss can significantly reduce individual risk; specific supplements are modest complements with support in established cognitive impairment; current Alzheimer's drugs are symptomatic with modest effects, and the new anti-amyloid drugs have a complex risk-benefit profile that requires specialist evaluation.
⏱ 3 min read
Dementia is a clinical syndrome of progressive cognitive decline with significant functional impact that affects tens of millions of people worldwide and whose prevalence increases exponentially with age: approximately 5% of people over 65, 20% of those over 80, and almost 50% of those over 85; Alzheimer's disease is the most frequent cause (60-70% of the total), followed by vascular dementia, dementia with Lewy bodies, and frontotemporal dementia. The good news, documented by the Lancet Commission on dementia, is that approximately 40% of dementia risk is attributable to modifiable factors across the lifespan, which opens an important margin for effective prevention.
Across the life course, the modifiable risk factors for dementia are:
Early life: low educational attainment (education builds cognitive reserve).
Midlife: hearing loss (hearing aids are protective), head injury (helmets, fall prevention), hypertension, excessive alcohol, obesity.
Later life: smoking, depression, physical inactivity, limited social contact, diabetes, air pollution.
To this list, more recent data add sleep quality and quantity and diet as additional factors with growing evidence.
Regular aerobic exercise: increases BDNF, improves cerebral blood flow, increases hippocampal volume, and is associated with significant reductions in dementia incidence in prospective cohorts. Combining it with strength training preserves muscle mass and prevents falls.
Mediterranean or MIND diet: the MIND diet (a combination of Mediterranean + DASH specifically designed for cognitive preservation) is supported by cohorts and some trials for reducing the incidence of Alzheimer's disease.
Control of cardiovascular factors: hypertension, diabetes, dyslipidemia, smoking; brain health depends crucially on vascular health.
Continuous cognitive stimulation: lifelong learning, reading, cognitive games, languages; builds cognitive reserve.
Active social ties: a robust predictor of cognitive preservation.
Sufficient, good-quality sleep: during deep sleep, the glymphatic system clears brain beta-amyloid; chronic sleep deprivation increases amyloid accumulation in prospective cohorts.
Treating hearing loss: hearing aid use in adults with hearing loss reduces cognitive decline according to recent trials.
B vitamins (folate, B12, B6) in people with elevated homocysteine: the VITACOG trial showed a significant reduction in brain atrophy with this combination.
Omega-3 EPA/DHA: adequate intake is associated with a lower incidence of dementia in prospective studies; the effect of specific supplementation in people with normal cognition is modest.
Vitamin D: subclinical deficiencies are associated with higher cognitive risk.
Citicoline (500-2000 mg/day): clinical support for cognitive impairment of cerebrovascular origin and mild vascular dementia.
Alpha-GPC: supported in European countries as a medication for cognitive impairment (Glatilin); the ASCOMALVA trial showed synergy with donepezil in mild Alzheimer's disease.
Lion's mane (Hericium erinaceus): the Mori 2009 trial showed significant improvements in mild cognitive impairment.
Spermidine (wheat germ extract): inverse association with mortality and cognitive decline in cohorts.
Curcumin, various polyphenols: with extensive preclinical support and modest clinical data.
Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine are symptomatic treatments for established Alzheimer's disease with a modest effect. In 2021-2024, the first anti-amyloid monoclonal antibodies (aducanumab, lecanemab, donanemab) appeared; they reduce brain amyloid and, marginally, clinical decline in early Alzheimer's disease; they have significant adverse effects (brain edema, microhemorrhages), and the data on their real-world clinical usefulness are the subject of active debate in neurology.
Significant and progressive cognitive complaints, especially with functional impact or reported by family members, require medical evaluation to rule out treatable causes (depression, B12 deficiency, hypothyroidism, sleep apnea, drugs with cognitive effects) and for early diagnosis if there is mild cognitive impairment or established dementia; early diagnosis allows for specific interventions and appropriate family planning.
Dementia is one of the conditions where prevention through sustained lifestyle has the greatest potential: control of cardiovascular factors, regular exercise, a Mediterranean diet, adequate sleep, continuous cognitive stimulation, active social ties, and management of hearing loss can significantly reduce individual risk; specific supplements are modest complements with support in established cognitive impairment; current Alzheimer's drugs are symptomatic with modest effects, and the new anti-amyloid drugs have a complex risk-benefit profile that requires specialist evaluation.